Physician profile
Stuart C Seigel
NPI 1073763983
$5,027.22
in general payments reported to CMS, 2019-2025
28 companies · $62.37 in 2025
The $62.37 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $2,130 · 2021: $1,085 · 2022: $190 · 2023: $60.01 · 2024: $266 · 2025: $62.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,319.92 | 2019-2021 | |
| Lilly USA, LLC | $416.08 | 2019-2022 | |
| Abbott Laboratories | $395.69 | 2019-2021 | |
| Corcept Therapeutics | $394.53 | 2020-2025 | Korlym |
| Dexcom, INC. | $306.50 | 2019-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $225.38 | 2019-2022 | |
| Amgen INC. | $138.82 | 2019-2021 | |
| Beta Bionics, INC. | $129.78 | 2024 | Ilet Bionic Pancreas |
| Sanofi-Aventis U.S. LLC | $80.44 | 2019-2021 | |
| Horizon Therapeutics Plc | $72.86 | 2020-2022 | |
| Mannkind Corporation | $69.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.39 | 2021 | |
| Radius Health, INC. | $57.73 | 2019-2022 | |
| Abbvie INC. | $54.98 | 2019 | |
| Tandem Diabetes Care, INC. | $36.19 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.41 | 2021 | |
| Insulet Corporation | $29.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.34 | 2019 | |
| Ibsa Pharma INC. | $23.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.88 | 2019 | |
| Zealand Pharma US, INC. | $20.19 | 2021 | |
| Shire North American Group INC | $19.39 | 2019 | |
| Becton, Dickinson and Company | $19.23 | 2019 | |
| Medtronic, INC. | $16.26 | 2021 | |
| Merck Sharp & Dohme LLC | $15.24 | 2019 | |
| Vivus LLC | $14.22 | 2019 | |
| Medtronic Minimed, INC. | $13.02 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Seigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.